Al's Comment:

 Impressive results: 64% overall response rate and 91% clinical benefit rate for pediatric low grade gliomas.    What makes this even more impressive is that there is very little research for this tumor type, which is the most common pediatric brain tumor type, and there are no approved treatments or even a standard of care for this type of tumor.  Best yet  - it is an oral drug and reasonable toxicity profile.


Posted on: 06/13/2022

Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!